Welcome to our dedicated page for Capstone Holding news (Ticker: CAPS), a resource for investors and traders seeking the latest updates and insights on Capstone Holding stock.
Capstone Holding Corp. (NASDAQ: CAPS) is a national building products distribution platform focused on stone and related exterior materials for residential and commercial construction. The news flow around Capstone centers on its acquisition activity, integration milestones, financial outlook, and capital structure decisions as it builds a scaled North American stone distribution network.
Recent news releases highlight Capstone’s disciplined M&A strategy, including the acquisition of Carolina Stone and the closing and integration of Canadian Stone Industries (CSI), a multi-location stone distributor. Coverage details how these acquisitions add revenue, expand the company’s geographic footprint across numerous U.S. states and Canada, strengthen its premium brand portfolio, and support margin expansion through purchasing power, logistics efficiencies, and cross-selling.
Investors following CAPS news will also find updates on Capstone’s financial performance and outlook. The company has issued press releases on record quarterly results, gross margin expansion, and its trajectory toward a stated revenue run-rate target, supported by organic growth and acquisitions. Additional materials, such as investor presentations and transcripts referenced in SEC filings, provide context on operating leverage, integration progress, and management’s focus on disciplined capital allocation.
Capital markets and balance-sheet developments are another recurring theme. News items discuss the extension of Capstone’s revolving credit facility with Berkshire Bank, the use of senior secured convertible notes, and the conversion of related-party debt into preferred equity. These updates explain how the company seeks to maintain liquidity, manage leverage, and preserve flexibility for future transactions.
Shareholder engagement and governance topics also appear in the news stream. Capstone has announced plans to publish an investor FAQ and invites shareholder questions on priorities such as organic growth and margin expansion. Proxy-related disclosures and SEC-referenced communications describe annual meeting proposals, stock incentive plans, and advisory votes on executive compensation.
For investors and analysts, the CAPS news page offers a consolidated view of these developments, making it easier to track acquisition announcements, integration updates, financial milestones, and governance actions that shape Capstone Holding Corp.’s building products distribution platform.
Summary not available.
Capstone Therapeutics Corp. held its Annual Meeting on March 2, 2023, primarily to elect three Class III Directors and ratify the appointment of GBQ Partners, LLC as its independent accounting firm. BP Peptides, LLC, a majority shareholder, holds 77.26% of outstanding shares and facilitated the meeting through written consent, allowing the election of John M. Holliman, III, Matthew E. Lipman, and Frederic J. Feldman until 2026. GBQ Partners was ratified for the fiscal years ending December 31, 2022, and 2023. Capstone has shifted its focus from biotechnology to managing TotalStone, LLC, a construction materials company, following the discontinuation of its drug development business.
Capstone Holding Corp. (OTCQB: CAPS) announced that BP Peptides, LLC converted $1,938,746 of accrued interest and debt into 78,333 shares of its common stock at an exercise price of $24.75 per share. This conversion increases Brookstone's total shares to 121,774, representing 77.26% of the company’s total stock. Capstone's operations shifted from biotechnology to managing interests in construction materials and equity interests in Diamond Products. For more details, refer to the 2021 Annual Report.
Capstone Therapeutics Corp. (OTCQB:CAPS) has officially changed its name to Capstone Holding Corp. as of February 25, 2022. This name change reflects the Company's strategic shift away from pharmaceutical development, following the licensing of its LipimetiX Development assets in December 2021. Capstone has since acquired a majority stake in a profitable building materials company, TotalStone, LLC, and a minority stake in Diamond Products, LLC, a consumer wellness firm. The new name aligns with its current focus on these operating businesses.
Capstone Therapeutics Corp. held its Annual Meeting of Stockholders on December 1, 2021, where two directors were elected and the appointment of GBQ Partners, LLC as independent accountants was ratified for the fiscal year ending December 31, 2021. The majority shareholder, BP Peptides, LLC, controlling 54.8% of shares, requested a consent voting format for the meeting. Capstone has transitioned from a biotechnology focus to managing construction materials through its subsidiary, TotalStone, LLC.
Capstone Therapeutics has acquired a minority interest in Diamond Products, LLC, a sexual wellness holding company, through its subsidiary Capstone Beta LLC. The acquisition, valued at around $8 million, involves a promissory note issued to Brookstone Partners, which holds a significant equity interest in Diamond. The transaction was overseen by a special committee of independent directors to ensure transparency and due diligence. This move marks a strategic shift as Capstone moves away from biotechnology into consumer products, specifically in the adult wellness sector.